Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
Retrieved on:
Monday, August 8, 2022 - 9:01pm
Molecule, FDA, Lupus nephritis, Drug Quality and Security Act, HIV disease progression rates, Forward-looking statement, GLOBE, Food, R, Mab, Autoimmunity, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, SEC, Clinical trial, Brain, Investment, Terminology, PD, Geographic atrophy, HD, GA, Patient, SAD, COVID-19, Eye, Severe cognitive impairment, Safety, G&A, Neurodegeneration, Complement component 1q, PK, Research, Securities Act of 1933, Second Half, Nasdaq, Fast Track, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, Pharmacokinetics, Disease, Vaccine, Pharmaceutical industry
BRISBANE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today outlined progress across its broad pipeline of fit-for-purpose product candidates and anticipated clinical milestones, and reported second quarter 2022 financial results.
Key Points:
- Annexon was founded with an ambitious goal: deliver game-changing treatments to patients suffering from complement-mediated diseases by stopping the classical complement cascade at its start.
- With the proceeds from our recent financing, we are well-positioned to execute our milestones with a multi-year runway into the second half of 2025.
- Overall, were invigorated by the promise of our platform and pipeline to make a meaningful difference in the treatment landscape for patients.
- Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late- stage clinical trials, with clinical data anticipated throughout 2022 and 2023.